160 related articles for article (PubMed ID: 38510043)
1. Comprehensive analyses of m1A regulator-mediated modification patterns determining prognosis in lower-grade glioma (running title: m1A in LGG).
Lei K; Sheng Y; Luo M; Liu J; Gong C; Lv S; Tu W; Ye M; Wu M; Xiao B; Fang H; Luo H; Liu X; Long X; Zhu X; Huang K; Li J
Heliyon; 2024 Mar; 10(6):e27510. PubMed ID: 38510043
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
3. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
4. Novel methylation-related long non-coding RNA clinical outcome prediction method: the clinical phenotype and immune infiltration research in low-grade gliomas.
Li Y; Li X; Yu Z
Front Oncol; 2023; 13():1177120. PubMed ID: 37228500
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and Predictive Value of Immune-Related Gene Pair Signature in Primary Lower-Grade Glioma Patients.
Lei K; Li J; Tu Z; Liu F; Ye M; Wu M; Zhu Y; Luo M; Lin L; Tao C; Huang K; Zhu X
Front Oncol; 2021; 11():665870. PubMed ID: 34123829
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive of N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer.
Liu J; Chen C; Wang Y; Qian C; Wei J; Xing Y; Bai J
Front Immunol; 2021; 12():746647. PubMed ID: 34777359
[TBL] [Abstract][Full Text] [Related]
7. Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas.
Ye L; Xu Y; Hu P; Wang L; Yang J; Yuan F; Wang Y; Zhang C; Tian D; Chen Q
Front Mol Neurosci; 2021; 14():720899. PubMed ID: 34776862
[No Abstract] [Full Text] [Related]
8. Machine learning identification of cuproptosis and necroptosis-associated molecular subtypes to aid in prognosis assessment and immunotherapy response prediction in low-grade glioma.
Miao Y; Liu J; Liu X; Yuan Q; Li H; Zhang Y; Zhan Y; Feng X
Front Genet; 2022; 13():951239. PubMed ID: 36186436
[TBL] [Abstract][Full Text] [Related]
9. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Zhang Q; Hong J
Front Genet; 2020; 11():363. PubMed ID: 32351547
[TBL] [Abstract][Full Text] [Related]
10. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma.
Shao D; Li Y; Wu J; Zhang B; Xie S; Zheng X; Jiang Z
Front Genet; 2022; 13():903117. PubMed ID: 35692827
[No Abstract] [Full Text] [Related]
11. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas.
Ji Q; Huang K; Jiang Y; Lei K; Tu Z; Luo H; Zhu X
Cancer Med; 2022 May; 11(9):2020-2035. PubMed ID: 35142109
[TBL] [Abstract][Full Text] [Related]
12. Novel immune checkpoint-related gene model to predict prognosis and treatment responsiveness in low-grade gliomas.
Guo Y; Bao J; Lin D; Hong K; Cen K; Sun J; Wang Z; Wu Z
Heliyon; 2023 Sep; 9(9):e20178. PubMed ID: 37809899
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
14. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
[TBL] [Abstract][Full Text] [Related]
15. A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.
Gao D; Zhou Q; Hou D; Zhang X; Ge Y; Zhu Q; Yin J; Qi X; Liu Y; Lou M; Zhou L; Bi Y
PeerJ; 2024; 12():e16874. PubMed ID: 38406287
[TBL] [Abstract][Full Text] [Related]
16. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
Front Genet; 2021; 12():718717. PubMed ID: 34925438
[No Abstract] [Full Text] [Related]
17. Prediction of Survival Outcome in Lower-Grade Glioma Using a Prognostic Signature with 33 Immune-Related Gene Pairs.
Chen S; Sun Y; Zhu X; Mo Z
Int J Gen Med; 2021; 14():8149-8160. PubMed ID: 34803397
[TBL] [Abstract][Full Text] [Related]
18. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
19. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.
Liu T; Sun L; Li ZZ; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Gastroenterol; 2023 May; 23(1):147. PubMed ID: 37170222
[TBL] [Abstract][Full Text] [Related]
20. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma.
Wen J; Zhao W; Shu X
Front Oncol; 2022; 12():1087762. PubMed ID: 36776374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
